Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative
Alzheimer's & Dementia · 2024-03 · 20 (3) · 1753-1770
DOI: 10.1002/alz.13560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 17.12.2023. Verfasst von Erlan Sanchez und 43 weiteren Autor:innen. Beteiligte Einrichtung: L.C. Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Frontotemporal Dementia, Cognitive Dysfunction, Alzheimer Disease. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Ontario Brain Institute, Alberta Innovates.
Abstract (Originalsprache)
INTRODUCTION We investigated whether novel plasma biomarkers are associated with cognition, cognitive decline, and functional independence in activities of daily living across and within neurodegenerative diseases. METHODS Glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau (p‐tau)181 and amyloid beta (Aβ) 42/40 were measured using ultra‐sensitive Simoa immunoassays in 44 healthy controls and 480 participants diagnosed with Alzheimer's disease/mild cognitive impairment (AD/MCI), Parkinson's disease (PD), frontotemporal dementia (FTD) spectrum disorders, or cerebrovascular disease (CVD). RESULTS GFAP, NfL, and/or p‐tau181 were elevated among all diseases compared to controls, and were broadly associated with worse baseline cognitive performance, greater cognitive decline, and/or lower functional independence. While GFAP, NfL, and p‐tau181 were highly predictive across diseases, p‐tau181 was more specific to the AD/MCI cohort. Sparse associations were found in the FTD and CVD cohorts and for Aβ 42/40 . DISCUSSION GFAP, NfL, and p‐tau181 are valuable predictors of cognition and function across common neurodegenerative diseases, and may be useful in specialized clinics and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- L.C. Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada.
- Dr. Sandra Black Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada.
Förderung
- CIHR
- Ontario Brain Institute
- Alberta Innovates
- Canadian Institutes of Health Research
- Vetenskapsrådet
Zitieren
APA
Sanchez, E., Wilkinson, T., Coughlan, G., Mirza, S., Baril, A. A., Ramirez, J., Binns, M. A., Black, S. E., Borrie, M., Dilliott, A. A., Dixon, R. A., Dowlatshahi, D., Farhan, S., Finger, E., Fischer, C. E., Frank, A., Freedman, M., Goncalves, R. A., Grimes, D. A., …, & Masellis, M. (2024). Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimer's & Dementia, 20(3), 1753-1770. https://doi.org/10.1002/alz.13560
Vancouver
Sanchez E, Wilkinson T, Coughlan G, Mirza S, Baril AA, Ramirez J, et al. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative. Alzheimer's & Dementia. 2024;20(3):1753-1770. doi:10.1002/alz.13560
BibTeX
@article{Sanchez2024,
author = {Sanchez, Erlan and Wilkinson, Tim and Coughlan, Gillian and Mirza, Saira and Baril, Andrée-Ann and Ramirez, Joel and Binns, Malcolm A and Black, Sandra E and Borrie, Michael and Dilliott, Allison A and Dixon, Roger A and Dowlatshahi, Dar and Farhan, Sali and Finger, Elizabeth and Fischer, Corinne E and Frank, Andrew and Freedman, Morris and Goncalves, Rafaella A and Grimes, David A and Hassan, Ayman and Hegele, Robert A and Kumar, Sanjeev and Lang, Anthony E and Marras, Connie and McLaughlin, Paula M and Orange, Joseph B and Pasternak, Stephen H and Pollock, Bruce G and Rajji, Tarek K and Roberts, Angela C and Robinson, John F and Rogaeva, Ekaterina and Sahlas, Demetrios J and Saposnik, Gustavo and Strong, Michael J and Swartz, Richard H and Tang-Wai, David F and Tartaglia, Maria Carmela and Troyer, Angela K and Kvartsberg, Hlin and Zetterberg, Henrik and Munoz, Douglas P and ONDRI Investigators, ONDRI Investigators and Masellis, Mario},
title = {Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {3},
pages = {1753--1770},
doi = {10.1002/alz.13560}
}
EUVIMED